Context Therapeutics Inc.

NasdaqCM:CNTX Stock Report

Market Cap: US$198.5m

Context Therapeutics Management

Management criteria checks 3/4

Context Therapeutics' CEO is Martin Lehr, appointed in Jan 2015, has a tenure of 11.33 years. total yearly compensation is $1.47M, comprised of 40.2% salary and 59.8% bonuses, including company stock and options. directly owns 1.18% of the company’s shares, worth $2.33M. The average tenure of the management team and the board of directors is 4.3 years and 5.2 years respectively.

Key information

Martin Lehr

Chief executive officer

US$1.5m

Total compensation

CEO salary percentage40.16%
CEO tenure11.3yrs
CEO ownership1.2%
Management average tenure4.3yrs
Board average tenure5.2yrs

Recent management updates

Recent updates

Analysis Article • Dec 19

We're Hopeful That Context Therapeutics (NASDAQ:CNTX) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analysis Article • Aug 03

Here's Why We're Not Too Worried About Context Therapeutics' (NASDAQ:CNTX) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analysis Article • Mar 30

We're Not Very Worried About Context Therapeutics' (NASDAQ:CNTX) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Aug 15

We Think Context Therapeutics (NASDAQ:CNTX) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. By way of example, Context...
Analysis Article • Mar 27

We're A Little Worried About Context Therapeutics' (NASDAQ:CNTX) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Sep 28

Here's Why Context Therapeutics (NASDAQ:CNTX) Must Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Jun 05

Will Context Therapeutics (NASDAQ:CNTX) Spend Its Cash Wisely?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Sep 27

Context to focus on ELONA trial, CLDN6 program, extends cash runway into 1Q24

Context Therapeutics (NASDAQ:CNTX) on Tuesday updated cash guidance to extend its runway into Q1 2024. The company plans to defer noncritical R&D activities, reduce future overhead and infrastructure expenditures, and prioritize its onapristone extended release (ONA-XR) ELONA Phase 1b/2 clinical trial and Claudin 6 (CLDN6) program. CNTX said it is evaluating ELONA clinical trial evaluating CNTX's oral progesterone receptor (PR) antagonist ONA-XR in combination with Menarini's elacestrant in estrogen receptor positive, PR+ HER2- metastatic breast cancer patients, who have previously been treated with a CDK4/6 inhibitor in Q4 this year and to report Phase 1b data in Q4 2023.
Analysis Article • Sep 15

We're Keeping An Eye On Context Therapeutics' (NASDAQ:CNTX) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Seeking Alpha • Aug 11

Context Therapeutics GAAP EPS of -$0.25 in-line

Context Therapeutics press release (NASDAQ:CNTX): Q2 GAAP EPS of -$0.25 in-line. Cash, cash equivalents, and restricted cash were $42.9 million.
Seeking Alpha • Aug 02

Context Therapeutics, Menarini to collaborate on breast cancer treatment combo trial

Context Therapeutics (NASDAQ:CNTX) and Italian pharmaceutical major Menarini Group have entered into a clinical trial collaboration and supply agreement to evaluate a breast cancer combination treatment, the companies said on Tuesday. The agreement will support the upcoming phase 1b/2 ELONA clinical trial evaluating CNTX's oral progesterone receptor (PR) antagonist ONA-XR in combination with Menarini's elacestrant in estrogen receptor positive, PR+ HER2- metastatic breast cancer patients who have previously been treated with a CDK4/6 inhibitor. Context (CNTX) will sponsor the trial while Menarini will supply elacestrant at no cost. CNTX said it anticipates starting the phase 1b/2 trial in Q4 this year. CNTX stock gained 5.8% to $2 in premarket trading.
Analysis Article • May 28

Companies Like Context Therapeutics (NASDAQ:CNTX) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Nov 02

Context Therapeutics: A New Biotech Issue With A Low Valuation And Significant Potential

Context Therapeutics is developing a potentially best-in-class Progesterone Receptor Antagonist that has already been validated in several female cancer indications. Biotech IPOs have accelerated throughout the pandemic with 76 companies raising in 2020 and 81 IPOs through the end of September of 2021. Context Therapeutics debuted last week at a far lower price than originally contemplated, while the sector (XBI) was almost 40% down from its February high. In my opinion, this company is undervalued and an opportunity exists to take a position before the larger market realizes the potential within Context's pipeline.

CEO Compensation Analysis

How has Martin Lehr's remuneration changed compared to Context Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$40m

Dec 31 2025US$1mUS$589k

-US$36m

Sep 30 2025n/an/a

-US$26m

Jun 30 2025n/an/a

-US$34m

Mar 31 2025n/an/a

-US$28m

Dec 31 2024US$1mUS$506k

-US$27m

Sep 30 2024n/an/a

-US$30m

Jun 30 2024n/an/a

-US$19m

Mar 31 2024n/an/a

-US$21m

Dec 31 2023US$861kUS$492k

-US$24m

Sep 30 2023n/an/a

-US$21m

Jun 30 2023n/an/a

-US$19m

Mar 31 2023n/an/a

-US$18m

Dec 31 2022US$1mUS$477k

-US$15m

Sep 30 2022n/an/a

-US$14m

Jun 30 2022n/an/a

-US$12m

Mar 31 2022n/an/a

-US$13m

Dec 31 2021US$2mUS$291k

-US$10m

Sep 30 2021n/an/a

-US$8m

Jun 30 2021n/an/a

-US$7m

Mar 31 2021n/an/a

-US$648k

Dec 31 2020US$250kUS$250k

US$1m

Dec 31 2019US$250kUS$250k

-US$6m

Compensation vs Market: Martin's total compensation ($USD1.47M) is about average for companies of similar size in the US market ($USD1.71M).

Compensation vs Earnings: Martin's compensation has increased whilst the company is unprofitable.

CEO

Martin Lehr (41 yo)

11.3yrs
Tenure
US$1,465,430
Compensation

Mr. Martin A. Lehr serves as Independent Director of Praesidia Biotherapeutics, Inc. He is the Co-founder, President, Chief Executive Officer and Director of Context Therapeutics Inc., since 2015. Mr. Lehr...

Leadership Team

NamePositionTenureCompensationOwnership
Martin Lehr
Co-Founder11.3yrsUS$1.47m1.18%
$ 2.3m
Jennifer Minai-Azary
CFO & Treasurer4.5yrsUS$866.14k0.087%
$ 172.8k
Alex Levit
Chief Legal Officer & Corporate Secretary5.1yrsUS$816.67k0.089%
$ 177.1k
Christopher Beck
Senior Vice President of Operations4.3yrsno datano data
Jeffrey Liebman
Associate Director of Accounting1.3yrsno datano data
Jennifer Dashnau
Senior Vice President of Technical Operations1.3yrsno datano data
Karen Chagin
Chief Medical Officerless than a yearno datano data
4.3yrs
Average Tenure
46.5yo
Average Age

Experienced Management: CNTX's management team is considered experienced (4.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Martin Lehr
Co-Founder11.3yrsUS$1.47m1.18%
$ 2.3m
Jennifer Stacey
Independent Director5.2yrsUS$122.64k0%
$ 0
Linda West
Independent Director5.2yrsUS$127.36k0%
$ 0
Philip Kantoff
Independent Director7.4yrsUS$111.14k0.0038%
$ 7.6k
Karen Smith
Independent Director1.7yrsUS$200.25k0%
$ 0
Luke Walker
Independent Director1.7yrsUS$111.14k0%
$ 0
Andrew Pasternak
Independent Chairman1.3yrsUS$159.03kno data
5.2yrs
Average Tenure
57yo
Average Age

Experienced Board: CNTX's board of directors are considered experienced (5.2 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/17 17:15
End of Day Share Price 2026/05/15 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Context Therapeutics Inc. is covered by 11 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Li Wang WatsekCantor Fitzgerald & Co.
Silvan TuerkcanCitizens JMP Securities, LLC
Jason KolbertD. Boral Capital LLC.